Signal Transduction and Targeted Therapy

Article	Citations
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	2226
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1782
Moving towards precision psychiatry: the hard nut of depression	1436
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1392
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	1181
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	1156
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	1144
Dopamine as a teaching signal: understanding its role in shaping individual behavior	1106
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT	1062
Correction: The Hippo signalling pathway and its implications in human health and diseases	1007
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	991
Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly	968
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	924
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	902
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	899
Correction: Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine	886
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	873
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	861
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	832
Sensory neurons: unveiling the symphony of wound healing	813
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	808
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	801
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	778
Identification of glutamine as a potential therapeutic target in dry eye disease	764
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	708

Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	684
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	673
Animal models for COVID-19: advances, gaps and perspectives	662
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	657
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	645
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	643
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	640
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	634
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	634
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	634
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	633
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	612
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	610
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	609
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	604
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	602
Phototherapy in cancer treatment: strategies and challenges	597
Neutrophil extracellular traps in homeostasis and disease	592
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	580
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	567
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)	562
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	558
Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism	556
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	548
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	528
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	511
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	503
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	492
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer	486
Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair	479
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	479
PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron	479
Top(ological-operon) secret behind the long-range transcriptional coupling	474
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy	463
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	463
Omicron spike protein: a clue for viral entry and immune evasion	463
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	454
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	448
Beyond borders: the choroid plexus-immune communication during neuroinflammation	439
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination	436
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	436
Platelets and diseases: signal transduction and advances in targeted therapy	427
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	412
The RING finger protein family in health and disease	404
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	402
Harnessing innate immune pathways for therapeutic advancement in cancer	386
Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects	376
Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis	373
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	371
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	362

Microbiota in health and diseases	355
Mind-body control: a new perspective on motor neuron function	355
Base editing: a promising tool to rescue spinal muscular atrophy	348
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	344
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	343
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	340
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	339
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	334
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	330
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	327
Nascent mRNA damage: depot and disposal	321
sRAGE alleviates SARS-CoV-2-induced pneumonia in hamster	321
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies	320
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	318
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	317
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	314
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	314
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	313
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	309
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	309
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	309
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	308
Persistent SARS-CoV-2 infection in asymptomatic young adults	306
Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia	306
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	304
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	303
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	303
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	303
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	299
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	296
Molecular insights of exercise therapy in disease prevention and treatment	292
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	291
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	285
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	284
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	283
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	279
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	273
Small molecules in the treatment of COVID-19	271
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	268
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	262
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	260
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy	260
Mitochondrial heterogeneity in diseases	259
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	257
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities	257
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	254
Lactate metabolism in human health and disease	254
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	253
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	252
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	247
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	245
Single-cell genomics: the human biomolecular and cell atlases	243
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	239
Back to pluripotency: fully chemically induced reboot of human somatic cells	234
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	233
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	229
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	229
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	228
Programmable synthetic receptors: the next-generation of cell and gene therapies	228
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	227
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	227
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	226
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	225
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	224
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	219
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	216
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	215
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	214
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	214
Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer	211
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	210
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels	199
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	199
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	199
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	197
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	197
Current landscape of innovative drug development and regulatory support in China	196
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	195
Signaling pathways and targeted therapies for psoriasis	195
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	193

mRNA-based therapeutics: powerful and versatile tools to combat diseases	193
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	181
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing	180
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	178
Activated STING: an ion channel to trigger non-interferon-related functions	177
Time’s up: mutation rate and lifespan	175
Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution	174
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	172
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	170
Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages	170
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	170
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	169
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	169
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	165
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	164
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	156
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury	156
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	154
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	154
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	151
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	150
Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone	150
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape	150
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	149
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	148
Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target	147
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates	145
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	145
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	145
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	144
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	144
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	144
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	144
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	144
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	143
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	143
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	142
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	141
Signaling pathways in obesity: mechanisms and therapeutic interventions	140
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	140
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	139
Artificial intelligence in cancer target identification and drug discovery	139
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	139
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	139
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	139
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	138
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	138
Targeted protein degradation: advances in drug discovery and clinical practice	137
Redox regulation: mechanisms, biology and therapeutic targets in diseases	137
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	136
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	136
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	136
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	135
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation	134
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	133
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	132
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	132
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern	132
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	131
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	131
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	131
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	130
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	125
Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure	125
SCGN deficiency is a risk factor for autism spectrum disorder	125
NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity	124
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	124
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	123
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	123
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	121
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	120
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	119
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	118
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	116
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	116
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	115
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	115
SLC7A11: a new regulator in diabetic wound healing	114
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread	114
The gasdermin family: emerging therapeutic targets in diseases	114
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	114
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy	113
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	113
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)	113
Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1	112
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal c	111
Intratumoural microbiota: a new frontier in cancer development and therapy	109
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	108
The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling	107
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	105
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial	105
Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1	105
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	104
The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis	104
CAR-T cell therapy for cancer: current challenges and future directions	104